About us

Driven by passion and curiosity for science, we aim for some of the most urgent but also most complex challenges in drug development.

Philipp Bürling

Philipp Bürling, MBA

CEO

Prof. Dr. Dieter Willbold

CSO

Prof. Dr. med. Oliver Peters

CMO
Dr. Antje Willuweit

Dr. Antje Willuweit

Director Preclinical Development
Dr. Dagmar Jürgens

Dr. Dagmar Jürgens

Director Clinical Development
Dr. Knut Adermann

Dr. Knut Adermann

Director CMC
Dr. Gunther Kauselmann

Dr. Gunther Kauselmann

Director Quality Management and Regulatory Compliance
Prof. Dr. Detlev Riesner

Prof. em. Dr. Dr. h.c. Detlev Riesner

Chairman
Dr. Johannes Schmiegel

Dr. Johannes Schmiegel

Prof. Dr. Jörg Breitkreutz

Prof. Dr. Jörg Breitkreutz

Prof. Dr. med. Gereon R. Fink

Prof. Dr. med. Gereon R. Fink

Prof. Dr. Holger Stark

Prof. Dr. Holger Stark

Prof. Dr. med. Inga Zerr

Prof. Dr. med. Inga Zerr

Our team consists of highly skilled and specialized scientists with different backgrounds. Scientific excellence is both a goal and a demand on ourselves.

Prof. Dr. Dieter Willbold

"Decades of research have gone into a unique treat­ment concept for neuro­degener­ative diseases. Priavoid continues to translate this concept into the development of efficient and safe drugs."

Prof. Dr. Dieter Willbold, Co-Founder

Prof. Dr. Dieter Willbold

Forschungszentrum Jülich / Sascha Kreklau

Our Network

As is well known, together we are stronger. Priavoid is proud of its network. Our most important partners include the Research Center Jülich (FZJ), Heinrich Heine University (HHU) and Prinnovation, a subsidiary of the German Federal Agency for Disruptive Innovation.

The Research Center Jülich and the Heinrich Heine University are the birthplaces of Priavoid. In addition, the Institute of Physical Biology (HHU) is headed by Prof. Dr. Dieter Willbold, CSO and co-founder of Priavoid. He was also director at the Institute of Structural Biochemistry (IBI-7, FZJ) for 20 years. All parties benefit from an intensive scientific exchange and collaboration in specific topics.

Prinnovation GmbH was founded as a subsidiary of the Federal Agency for Disruptive Innovation (SPRIN-D). In 2021, Prinnovation and Priavoid established a research collaboration to implement the further clinical development of our Alzheimer's program PRI-002.

Forschungszentrum Jülich
SPRIN-D
Prinnovation